Thursday, May 10, 2012

Guided Therapeutics (OTCBB: GTHP) Submits Response to FDA for LuViva® Advanced Cervical Scan

Guided Therapeutics (OTCBB: GTHP) Submits Response to FDA for LuViva® Advanced Cervical ScanAtlanata, GA 5/10/12 (StreetBeat) – Guided Therapeutics, Inc., (OTCBB: GTHP), today announced that it has submitted its formal response to the U.S. Food and Drug Administration (FDA) not-approvable letter for the LuViva® Advanced Cervical Scan, which the Company received in January. The Company’s response provided additional information as requested by the agency and also included a request for a meeting with FDA to determine a path forward for approval.

The Company also recently provided additional safety testing information in support of the application for the CE mark as requested by its reviewer and believes it remains on track to receive approval to market LuViva® in the 27 countries that comprise the European Union in the second quarter, as previously anticipated.

“We believe that by working with FDA, we can achieve approval in the U.S. for LuViva and provide women with access to new technological advancements to detect cervical disease at an earlier stage, when it can be better treated,” said Mark L. Faupel, Ph.D., President and CEO of Guided Therapeutics, Inc. “We also believe that LuViva remains on track to receive the CE mark in the second quarter. There were no questions regarding our clinical data. We continue to build up our international distribution network and introduce LuViva to the medical community at various medical conferences in anticipation of a product launch in the second half of 2012.”

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which eliminates costly, painful and unnecessary testing. LuViva is designed for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva®Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP.OB - News) (OTCQB: GTHP.OB - News) is developing a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The Company’s first planned product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics has also entered into a partnership with Konica Minolta Opto to develop a non-invasive test for Barrett’s Esophagus using the technology platform. For more information, visit: www.guidedinc.com.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

No comments:

Post a Comment